- 专利标题： Peptide-based in vivo siRNA delivery system
-
申请号： US13326433申请日： 2011-12-15
-
公开(公告)号： US08501930B2公开(公告)日： 2013-08-06
- 发明人: David B. Rozema , Darren H. Wakefield , David L. Lewis , Jon A. Wolff , Andrei V. Blokhin , Jonathan D. Benson , Jeffrey C. Carlson , Philipp Hadwiger , Eric A. Kitas , Torsten Hoffmann , Kerstin Jahn-Hofmann , Peter Mohr , Hans Martin Mueller , Guenther Ott , Ingo Roehl
- 申请人： David B. Rozema , Darren H. Wakefield , David L. Lewis , Jon A. Wolff , Andrei V. Blokhin , Jonathan D. Benson , Jeffrey C. Carlson , Philipp Hadwiger , Eric A. Kitas , Torsten Hoffmann , Kerstin Jahn-Hofmann , Peter Mohr , Hans Martin Mueller , Guenther Ott , Ingo Roehl
- 申请人地址： US WI Madison
- 专利权人： Arrowhead Madison Inc.
- 当前专利权人： Arrowhead Madison Inc.
- 当前专利权人地址： US WI Madison
- 代理商 Kirk Ekena
- 主分类号： C07H21/04
- IPC分类号： C07H21/04 ; C07H21/02 ; C07K5/00
摘要：
The present invention is directed compositions for targeted delivery of RNA interference (RNAi) polynucleotides to hepatocytes in vivo. Targeted RNAi polynucleotides are administered together with co-targeted melittin delivery peptides. Delivery peptides provide membrane penetration function for movement of the RNAi polynucleotides from outside the cell to inside the cell. Reversible modification provides physiological responsiveness to the delivery peptides.
公开/授权文献
- US20120165393A1 Peptide-Based In Vivo siRNA Delivery System 公开/授权日：2012-06-28
信息查询
